Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response
TIGIT serves as a biomarker in SCLC, with its high expression indicating favorable prognosis and treatment response. These effects may be due to TIGIT's unique immune landscape and its association with other immune checkpoints.
Authors
- Jianming Ying (ORCID: https://orcid.org/0000-0003-2692-4052)
- Jiyan Dong
- Bingzhi Wang (ORCID: https://orcid.org/0000-0001-7330-3107)
- Peng Wu (ORCID: https://orcid.org/0000-0003-2676-508X)
- Wenchao Liu (ORCID: https://orcid.org/0000-0002-7343-6759)
- Li Liu (ORCID: https://orcid.org/0000-0002-9678-9653)
- Chaoqi Zhang (ORCID: https://orcid.org/0000-0002-6907-2542)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1007/s00262-025-03985-6
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Beijing Municipal Health Commission